Research programme: histone deacetylase inhibitors - Pharmacyclics

Drug Profile

Research programme: histone deacetylase inhibitors - Pharmacyclics

Alternative Names: CRA-026440; PCI-34051

Latest Information Update: 11 Dec 2015

Price : $50

At a glance

  • Originator Celera Genomics Group
  • Developer Pharmacyclics
  • Class Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Autoimmune disorders

Most Recent Events

  • 26 May 2015 Pharmacyclics has been acquired by AbbVie
  • 01 Oct 2014 No development reported - Preclinical for Autoimmune disorders in USA (PO)
  • 25 Sep 2014 Pharmacyclics and Servier terminate their agreement to co-develop histone deacetylase inhibitors for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top